Non-Hodgkin Lymphoma Therapeutics Market Size & Share, by Type of Therapy (Chemotherapy, Radiation Therapy, Target Therap); Cell Type (B-Cell Lymphoma, T-Cell Lymphoma); Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5584
  • Published Date: Jan 29, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Non-Hodgkin Lymphoma Therapeutics Market size is poised to cross USD 20 Billion by the end of 2036, expanding at a CAGR of 8% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of non-hodgkin lymphoma therapeutics was USD 8 Billion. The growth of the market is set to be encouraged by growing prevalence for non-Hodgkin lymphoma (NHL). Throughout the past few decades, there has been a steady increase in the incidence of non-Hodgkin's lymphoma (NHL). For instance, in case of America, NHL is expected to be diagnosed in over 80,549 Americans (over 35,769 women and close to 44,879 men) in 2023. Hence, the demand for non-Hodgkin lymphoma therapeutics market is set to rise.

Furthermore, there has been surge in research in this field in order to deal with the growing cases. For instance, Researchers funded by the NCI are improving our knowledge of lymphoma treatment. The lymph system, that's a component of the body's immune system, is the place where all lymphomas begin.  However, there are over 70 distinct disease subgroups. Scientists are currently able to create more individualized treatments for different subtypes of lymphoma owing to advances in understanding the gene alterations that might cause the disease.

Non-Hodgkin Lymphoma Therapeutics Market overview
Get more information on this report: Request Free Sample PDF

Non-Hodgkin Lymphoma Therapeutics Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2023)

~USD 8 Billion

Forecast Year Market Size (2036)

~USD 20 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Non-Hodgkin Lymphoma Therapeutics Market: Growth Drivers and Challenges


Growth Drivers

  • Surge in Geriatric Population - According to the World Health Organization, one in six individuals globe are going to be 60 years of age or older by 2030. This will culminate in a rise in the proportion of people over 60 from 1 billion in 2020 to 1.4 billion at this point. At a median age of 67 years at diagnosis, non-Hodgkin lymphoma (NHL) mostly impacts older persons. Adults with NHL who are older may find treatment difficult. A decrease in functional reserve that is unique to each person as they age raises the possibility of treatment-related toxicity and death. Furthermore, the primary determinant of a patient's survival following a cancer diagnosis is their age. As a result, the need for non-Hodgkin Lymphoma therapeutics is rising.
  • Rise in Environmental Exposure - Strong evidence from earlier studies has linked environmental factors to the development of NHL. The aetiology of lymphoma has been associated with a number of infectious agents, including Epstein-Barr virus (EBV), human herpes virus, and human T-lymphotropic virus type I. These viruses can cause immunodeficiency syndromes, alter normal lymphocytes, or stimulate the immune system chronically. Severe NHLs are clearly associated with human immunodeficiency virus (HIV) infection; nevertheless, the percentage of NHL attributable to the HIV epidemic varies according on the subtype.
  • Growth in Approval of Medications - The non-Hodgkin lymphoma therapeutics market faces a significant unmet demand for the treatment of blood cancer, despite the availability of numerous authorized medicines for different forms of the disease. Many chemotherapy medications are currently ruling the field of cancer treatment for a variety of cancer types. However, in comparison to chemotherapy, immunotherapies and targeted treatments hold a larger non-Hodgkin lymphoma therapeutics market share. This may be due to restrictions such the chemotherapies' long-lasting side effects, which lower the patient's commitment to the treatment. In addition, immunotherapies and targeted therapies have grown into a dominant class of medicines, regulating particular proteins and protein targets. The non-Hodgkin lymphoma therapeutics market is expected to rise due in part to the increasing R&D in this area and the ongoing clinical studies of late-stage molecules.


  • Limited Access to Treatment - The fact that most patients globally lack access to therapy is one of the biggest issues facing the sector. Almost every licensed medications for the treatment of non-Hodgkin lymphoma are available in the majority of North American and European countries. However, with developing and poor economies, there are few therapeutic choices available for the treatment of diseases. Although non-Hodgkin lymphoma and other blood malignancies are highly prevalent in these nations, patients find it challenging to receive treatment on time due to a lack of available therapeutic alternatives.
  • Lack of Efficient Healthcare Technology
  • High Price of the Treatment - A sizeable portion of the patient population in many developing nations is unable to pay for treatment owing to the high cost of therapies, in part because patient aid programmes are not readily available, health insurance is not well understood, and there is a dearth of sophisticated healthcare infrastructure. Hence, on account of this factor the non-Hodgkin lymphoma therapeutics market is set to experience hinder.

Non-Hodgkin Lymphoma Therapeutics Segmentation

Type of Therapy (Chemotherapy, Radiation Therapy, Target Therap)

The chemotherapy segment in the non-Hodgkin lymphoma therapeutics market is expected to gather the highest share of about 50% during the forecast period. Chemotherapy is a highly effective treatment for cancer since it stops the cancer cells from spreading more and increasingly widely. It is the most used cancer treatment, working to stop the growth of tumors and eliminate cancer cells. Furthermore, chemotherapy continues to be a mainstay since it works for a wide range of NHL subtypes, despite the advent of new therapies. The fact that healthcare practitioners are familiar with it and its well-established protocols add to its ongoing demand. Furthermore, chemotherapy is frequently a financially advantageous course of treatment in areas with limited resources.

Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies)

The hospital pharmacies segment is expected to hold 50% share of the global non-Hodgkin lymphoma therapeutics market by 2036. The non-hodgkin lymphoma therapies market is dominated by the hospital pharmacy segment for a number of reasons. Major cancer treatment facilities include hospitals, which offer complete care, including diagnosis, therapy, and follow-up. The efficient distribution and administration of several medicines are made possible by this focused strategy. Hospitals are also equipped with the facilities needed to handle and store specialized treatments like targeted therapies and chemotherapy. Further, owing to rising number of hospitals the market is estimated to grow. The overall number of hospitals globally as of 2021 is estimated to be over 164,000.

Our in-depth analysis of the global non-Hodgkin lymphoma therapeutics market includes the following segments:

          Type of Therapy

  • Chemotherapy
  • Radiation Therapy
  • Target Therapy

          Cell Type

  • B-Cell Lymphoma
  • T-Cell Lymphoma

          Distribution Channel

  • Retail Pharmacies & Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Non-Hodgkin Lymphoma Therapeutics Industry - Regional Synopsis

North American Market Forecasts

The North America non-Hodgkin lymphoma therapeutics market is poised to generate the highest share of about over 30% during the forecast period. This growth is set to be dominated by growing advancement and adoption of latest technology such as AI. For instance, in the areas of radiology, neurology, and pathology, the Food and Drug Administration (FDA) in the United States will have assessed and authorized over 500 medical AI devices by 2023. Artificial intelligence (AI) has become so popular in the last few years that a lot of money has been spent on its development and commercialization in the medical industry. Furthermore, there has been launch of various well-regulated frame work which has influenced the launch of various treatment options in the region. Furthermore, since the healthcare sector is one of the most regulated in the US, healthcare compliance is an important and rapidly expanding field within the sector. Hence, all these factors are set to dominate the market expansion in this region.  

APAC Market Analysis

The Asia Pacific non-Hodgkin lymphoma therapeutics market is also estimated to rise over the coming years.  The major element to encourage the growth of the market in this region is rising demand for generic manufacturers. Furthermore, generic drugs are considered to be most affordable. Hence, with the availability of low-income group the market demand for generic drug is more in this region. Further, the quality of these drugs is same of that branded drugs which is why the demand for it is high. As a result, the rising need for generic drug the market for Non-Hodgkin lymphoma therapeutics is also set to rise in this region. 

Research Nester
Non-Hodgkin Lymphoma Therapeutics Market size
Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Non-Hodgkin Lymphoma Therapeutics Market

    • AbbVie, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GSK plc.  
    • Novartis AG
    • Bayer AG
    • Bausch Health Companies Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma


In The News

  • November 15, 2023: The FDA approved SIRPant-M's investigational new drug (IND) application in May 2023 after reviewing preclinical data that indicated the medication was effective against a range of solid tumours as well as hematologic tumours.
  • May 19, 2023: AbbVie announced that EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) that have undergone two or more lines of systemic therapy and are relapsed or refractory (R/R).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5584
  • Published Date: Jan 29, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The major factors driving the growth of the market are surge in geriatric population, rise in environmental exposure, and growth in approval of medications.

The market size of Non-Hodgkin lymphoma therapeutics is anticipated to attain a CAGR of 8% over the forecast period, i.e., 2024-2036.

The major players in the market AbbVie, Inc., Teva Pharmaceutical Industries Ltd., Sanofi, Pfizer Inc. are and others.

The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Non-Hodgkin Lymphoma Therapeutics Market Report Scope

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying